-+ 0.00%
-+ 0.00%
-+ 0.00%

Ensysce Biosciences Enrolls 50% Of Subjects Targeted For Interim Review In Phase 3 Trial Of PF614

Benzinga·01/28/2026 13:04:29
Listen to the news

~ Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~